KN044 / Alphamab - LARVOL DELTA

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy. (PubMed, Int Immunopharmacol) - "Therapeutic antibodies targeting CTLA-4, including the FDA-approved agents ipilimumab and tremelimumab, achieve checkpoint blockade through steric occlusion of the B7-binding interface, inhibition of transendocytosis, and Fc-mediated regulatory T-cell depletion...Other antibodies, including JS007, have entered clinical evaluation, while structurally characterized agents such as mipi.4 and KN044 provide preclinical and translational insights. Emerging engineering strategies, Fc-optimized variants, tumor-activated prodrug formats, bispecific antibodies, and alternative scaffolds such as nanobodies and DARPins are now translating these structural insights into next-generation therapeutics with improved selectivity and reduced immune-related adverse events. By connecting atomic-level receptor recognition to clinical outcome, this review provides a mechanistic foundation for the rational design of next-generation CTLA-4 therapeutics with improved efficacy and reduced..."

Journal • Review • Immunology • Oncology

KN044 - Asia: an AMR hot zone (ESCMID Global 2025) - "This keynote lecture will give an overview of AMR in ASIA and review the results of the epidemiological study ACORN-HAI. Additionally, it will explore strategies for developing clinical trial capacity in many low- and middle-income countries in Asia and why this is vital in combating AMR in the long term."

Infectious Disease

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Jun 2022 ➔ Jun 2023

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Trial completion date: Dec 2021 ➔ Aug 2022; Trial primary completion date: Sep 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Not yet recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD

Clinical • New P1 trial